In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.
about
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinoloneFocus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infectionsSuppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odysseyDetermination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and ValnemulinDoes High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance?Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infectionsDrug interactions and the evolution of antibiotic resistance.Efficacy of antibiotic treatment of implant-associated Staphylococcus aureus infections with moxifloxacin, flucloxacillin, rifampin, and combination therapy: an animal study.Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureusMutant selection window and characterization of allelic diversity for ciprofloxacin-resistant mutants of Rhodococcus equi.Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profilingIn vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model.Is selection relevant in the evolutionary emergence of drug resistance?The changing face of antibiotic prescribing: the mutant selection window.Setting and revising antibacterial susceptibility breakpoints.Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infectionRecent developments in the clinical activity of topoisomerase-1 inhibitors.Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.Mutant selection window hypothesis updated.Optimizing drug exposure to minimize selection of antibiotic resistance.Relationship between Cefquinome PK/PD Parameters and Emergence of Resistance of Staphylococcus aureus in Rabbit Tissue-Cage Infection Model.Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniaeFluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection modelNovel concentration-killing curve method for estimation of bactericidal potency of antibiotics in an in vitro dynamic model.Quinolones: action and resistance updated.Using In Vitro Dynamic Models To Evaluate Fluoroquinolone Activity against Emergence of Resistant Salmonella enterica Serovar Typhimurium.Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria.Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically?Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.Susceptibility and PK/PD relationships of Staphylococcus aureus strains from ovine and caprine with clinical mastitis against five veterinary fluoroquinolones.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.
P2860
Q24629223-13A1E0B4-0D88-496A-9198-09D34F0FC01CQ26746197-457EA57B-58C4-4C80-A9E2-D51EE2247562Q26771850-8ACB5055-85E3-4D9C-8281-B97771D13C26Q28235095-D021A453-1F5A-4082-8C2E-6810F53D5187Q28468397-5190B993-6D62-4F53-87E0-6E55B4C454F4Q28552950-FDECFC68-09D6-4FAD-BD59-8F5D9FBF7467Q33767602-D82CECAD-EC86-429A-BC85-E78DFB96E100Q33792926-29282B78-4693-453F-B939-0280C7A59E2CQ33812856-3BBDA510-2BFA-48A3-B44F-83899163AA45Q33836597-A958FA41-9813-4F12-8B0B-915FB0847DBCQ34045286-CE384D0D-EF2A-481F-AA75-38EABE6A0035Q34596344-E35008E6-A376-48A2-971E-8ECE67166F29Q34721695-0F912BBC-437A-4959-A6E8-3930738F7FCDQ34721706-3F3B0B61-1AC6-47F6-A313-B8D8D832377DQ34788573-93E67C90-1301-4B69-B9EB-86A0FB6C5DE1Q35826386-D680A01E-529D-43F6-AB89-CB1D6EC395EBQ35875929-8DA25A0C-243A-44D1-B4A1-C55B742A3366Q35913176-920A77A5-2C5F-453B-99B2-B59D6CF56ADCQ36095024-EE787ADA-1DFF-437B-8CCB-4B6955941508Q36234871-2D910841-202E-4DC4-A201-50FB4D80C40EQ36505518-D05BDB32-2D93-4296-BFD9-B8B05D7BA335Q36728061-C888F4F4-B863-4138-8475-D77300E214B3Q36903693-93B4C569-82D1-4CB8-9657-79BCF8C5E3A2Q36976649-3BF46F31-3134-474B-8C36-88B54EAE53A9Q37023175-23FBA688-351B-4B3C-8D70-9056C81FB08BQ37191156-C4C7DAB4-9CBA-421E-93C9-F389949F1726Q37274635-00E26CF3-553A-488A-A168-A0FD615E0A84Q37568944-B8E87A64-5D22-412A-BF48-FE59AA9DF91CQ37595559-A53089AC-C2AF-4176-A38D-DBCD32A8D47DQ37613055-E104AAB4-6BA4-4CA9-B60C-AFF4C2BE3438Q37624733-660885B4-917E-475A-B2FF-B778DFE2CDE6Q37988861-C8F99C4E-1D78-4A4F-B23C-0EAA2A8BE9F9Q38664871-A91AF724-D125-43EC-93FE-71562D6481F4Q38692072-325D5F00-9493-4191-915F-AAFDA4246E0CQ38740127-D18F4BAD-523B-40EA-A1C9-912D63866194Q38740720-57785FF4-81F8-432E-A1D8-C8082BB434CEQ38899404-0E6A7766-3447-4FBB-9241-131DD4BBF09CQ38954542-355CCF8E-9AF4-49B5-96D4-12F7B90074CBQ39293585-D1BA9A63-C13B-4CA1-984E-439E9950A367Q39660010-F46665E7-BCA8-46F7-B69A-17A5A869DE24
P2860
In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
In vitro pharmacodynamic evalu ...... against Staphylococcus aureus.
@en
In vitro pharmacodynamic evalu ...... against Staphylococcus aureus.
@nl
type
label
In vitro pharmacodynamic evalu ...... against Staphylococcus aureus.
@en
In vitro pharmacodynamic evalu ...... against Staphylococcus aureus.
@nl
prefLabel
In vitro pharmacodynamic evalu ...... against Staphylococcus aureus.
@en
In vitro pharmacodynamic evalu ...... against Staphylococcus aureus.
@nl
P2093
P2860
P1476
In vitro pharmacodynamic evalu ...... against Staphylococcus aureus
@en
P2093
Alexander A Firsov
Irene Y Lubenko
Karl Drlica
Sergey N Vostrov
Stephen H Zinner
P2860
P304
P356
10.1128/AAC.47.5.1604-1613.2003
P407
P50
P577
2003-05-01T00:00:00Z